Please assess the completion status of the following clinical trial:

Trial Title: BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Written informed consent must be obtained before any assessment is performed.~* Males and females ages 40 to 80 years~* Smoking history of at least 10 pack-years~* Diagnosis of COPD according to GOLD guidelines (GOLD, 2010), with a post-bronchodilator FEV¬1 \< 80% predicted and FEV1/FVC ratio \< 0.70~* BMI \<20 kg/m2 or skeletal muscle mass index by DXA \< 7.25 kg/m2 for men or \<5.45 kg/m2 for women.~* In general stable health, including managed COPD, by past medical history, physical examination, vital signs at baseline as determined by the investigator.~Exclusion criteria:~* Patients with MRC dyspnoea grade 5 (i.e. patients too breathless to leave the house or breathless when dressing)~* Plans for lung transplantation or lung reduction surgery within four months of enrollment~* Patients participating in a formal pulmonary rehabilitation program within 3 months of dosing~* History of malignancy of any organ system (other than excised non-melanomatous carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.~* Diseases other than cancer known to cause cachexia or muscle atrophy, including but not limited to congestive heart failure of any stage, chronic kidney disease (estimated GFR \< 30 mL/min using the MDRD equation), rheumatoid arthritis, primary myopathy, stroke, HIV infection, tuberculosis or other chronic infection, uncontrolled diabetes mellitus, etc.~* Inflammatory bowel disease, celiac disease, short bowel syndrome, pancreatic insufficiency~* Use of any prescription drugs known to affect muscle mass, including androgen supplements, anti-androgens (such as LHRH agonists), anti-estrogens (tamoxifen, etc.) recombinant human growth hormone (rhGH), insulin, oral beta agonists, megestrol acetate, dronabinol, metformin, etc.~* Hemoglobin concentration below 11.0 g/dL at screening.~* Liver disease or liver injury.~* Use of other investigational drugs at the time of enrollment, or within 30 days and for any other limitation of participation in an investigational trial based on local regulations.~* Women of child-bearing potential.~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- BYM338 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).